NASDAQ:MGTA Magenta Therapeutics (MGTA) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.68▼$0.7650-Day Range$0.36▼$0.7652-Week Range$0.32▼$2.07Volume376,000 shsAverage Volume848,835 shsMarket Capitalization$42.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Magenta Therapeutics alerts: Email Address Ad Weiss RatingsAmerica dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.Click here and follow the three simple steps Martin shares in this video to protect your savings whi About Magenta Therapeutics Stock (NASDAQ:MGTA)Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Weiss RatingsAmerica dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.Click here and follow the three simple steps Martin shares in this video to protect your savings whi MGTA Stock News HeadlinesAugust 30, 2024 | msn.comDelhi Metro Phase-IV: Safety nod in, Magenta Line extension may open next monthAugust 15, 2024 | finance.yahoo.comMagenta Buyer LLC Raises $400 Million of New CapitalSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… July 25, 2024 | finance.yahoo.comMagenta secures $105m to trial world’s smallest heart pumpJuly 23, 2024 | finance.yahoo.comMagenta Medical Closes $105M Financing Led by Novo HoldingsJuly 23, 2024 | wsj.comHeart-Pump Developer Magenta Medical Raises $105 MillionMay 21, 2024 | msn.comNew Caledonia riots: Mercy flight leaves Noumea Magenta Aerodrome, more evacuations likely throughout weekMay 15, 2024 | msn.comMalcolm McDowell, Jacob Ward to Lead Vietnam Draft Drama ‘Summerhouse,’ Magenta Light Studios Launching Sales at Cannes (EXCLUSIVE)September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… May 9, 2024 | yahoo.comMagenta Journal announced as the new digital Muskingum University news publicationMay 2, 2024 | msn.comMagenta Mobility And Kuehne+Nagel Partner To Electrify Road Logistics In IndiaApril 22, 2024 | msn.comWhen Red-Hot Isn't Enough: New Government Heat Risk Tool Sets Magenta as Most Dangerous LevelApril 13, 2024 | msn.comWhat's Included In T-Mobile's Magenta Max 55+ Plan (And How It Compares To Others)April 2, 2024 | msn.comMagenta the horse rescued from Fenland river by fire crews after becoming spookedMarch 26, 2024 | seekingalpha.comPSTX Poseida Therapeutics, Inc.March 20, 2024 | seekingalpha.comDNTH Dianthus Therapeutics, Inc.February 23, 2024 | finanznachrichten.deTEOCO's new framework drives Zero Touch Operational Automation at Magenta TelekomFebruary 22, 2024 | finance.yahoo.comTEOCO's New Framework drives Zero Touch Operational Automation at Magenta TelecomSee More Headlines Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:MGTA CUSIPN/A CIK1690585 Webwww.magentatx.com Phone(857) 201-2700FaxN/AEmployees67Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.88% Return on Assets-57.27% Debt Debt-to-Equity RatioN/A Current Ratio19.49 Quick Ratio19.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book0.57Miscellaneous Outstanding Shares60,665,000Free Float51,456,000Market Cap$42.44 million OptionableNot Optionable Beta2.12 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Stephen F. Mahoney J.D. (Age 51)MBA, Pres, Chief Financial & Operating Officer and Treasurer Comp: $637.21kShan WuHead of Investor RelationsMr. Thomas W. Beetham J.D. (Age 53)MBA, Chief Legal Officer & Sec. Ms. Catherine MonaghanHead of Clinical Devel. OperationsMr. Jim HaneySr. Director of Investor RelationsKey CompetitorsActuate TherapeuticsNASDAQ:ACTULianBioNASDAQ:LIANPHAXIAM TherapeuticsNASDAQ:PHXM9 Meters BiopharmaNASDAQ:NMTRPolarityTENASDAQ:PTEIQView All Competitors MGTA Stock Analysis - Frequently Asked Questions How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics, Inc. (NASDAQ:MGTA) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02. When did Magenta Therapeutics' stock split? Magenta Therapeutics shares split on the morning of Thursday, September 7th 2023. The 2-1 split was announced on Thursday, September 7th 2023. The newly issued shares were payable to shareholders after the market closes on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What is Jason Gardner's approval rating as Magenta Therapeutics' CEO? 3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. When did Magenta Therapeutics IPO? Magenta Therapeutics (MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE) and Aldeyra Therapeutics (ALDX). This page (NASDAQ:MGTA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Magenta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Magenta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.